Colorado-based biotech startup Enveda, which uses AI to discover new drugs from natural sources, secured $311 million in Series E funding at a $2 billion valuation—double its valuation from a year ago.
Enveda's latest funding round reflects growing investor confidence in AI-driven drug discovery from natural compounds. The $2 billion valuation marks significant momentum for the startup, which has doubled its value in 12 months.
The company leverages artificial intelligence to identify potential pharmaceutical compounds in nature, a approach that could accelerate traditional drug development timelines. Natural product-based drug discovery has historically been time-intensive, making AI applications particularly valuable in the space.
Enveda joins a wave of biotech companies integrating AI into their core operations. The sector has attracted substantial venture capital as investors bet on computational methods to reduce development costs and improve success rates.
The Series E round underscores the market's appetite for biotech innovation at scale. At $2 billion, Enveda now competes with established players in the AI-enabled drug discovery space, though it remains earlier-stage compared to fully commercialized pharma companies.
The company's Colorado base positions it within a growing biotech hub, though most major pharmaceutical innovation remains concentrated in coastal regions. This funding could support expansion across research capabilities, personnel, and clinical validation efforts.
Details on the funding round's lead investors and use of proceeds were not immediately disclosed in available reports.
Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.
Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.
Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.
Portuguese surveillance drone maker Tekever secured $580 million in funding led by UC Investments, reaching a $6.4 billion valuation. The raise follows a major £400 million, 10-year contract with UK Ministry of Defence.